GW Pharmaceuticals PLC (GWPH)
Stock Price:
$135.37 USD
2.50 (1.88%)
Updated Aug 4, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
4.20B |
| Revenue (ttm) |
392.72M |
| Net Income (ttm) |
33.08M |
| Shares Out |
31.08M |
| EPS (ttm) |
1.07 |
| PE Ratio |
126.51 |
| Forward PE |
136.99 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Aug 4, 2020 |
| Last Price |
$135.37 |
| Previous Close |
$132.87 |
| Change ($) |
2.50 |
| Change (%) |
1.88% |
| Day's Open |
133.31 |
| Day's Range |
132.00 - 135.37 |
| Day's Volume |
260,199 |
| 52-Week Range |
67.98 - 175.35 |
More Stats
| Market Cap |
4.20B |
| Enterprise Value |
3.73B |
| Earnings Date (est) |
Aug 6, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
31.08M |
| Float |
30.36M |
| EPS (basic) |
0.011 |
| EPS (diluted) |
1.07 |
| FCF / Share |
-0.74 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
0.79% |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
4.39M |
| Short Ratio |
15.67 |
| Short % of Float |
n/a |
| Beta |
1.94 |
| PE Ratio |
126.51 |
| Forward PE |
136.99 |
| P/FCF Ratio |
n/a |
| PS Ratio |
10.70 |
| PB Ratio |
5.64 |
| Revenue |
392.72M |
| Operating Income |
-74.28M |
| Net Income |
33.08M |
| Free Cash Flow |
-23.07M |
| Net Cash |
475.75M |
| Net Cash / Share |
15.33 |
| Gross Margin |
72.35% |
| Operating Margin |
-18.91% |
| Profit Margin |
8.40% |
| FCF Margin |
-5.87% |
| ROA |
-5.79% |
| ROE |
4.88% |
| ROIC |
15.90% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (16)
| Buy |
15 |
| Overweight |
0 |
| Hold |
1 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$190.50*
(40.73% upside)
Low
140
Current: $135.37
High
275
Target: 190.50
*Average 12-month price target from 16 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 |
|---|
| Revenue | 311 | 12.74 | 8.63 | 12.73 |
| Revenue Growth | 2344.31% | 47.61% | -32.22% | - |
| Gross Profit | 284 | 6.75 | 4.11 | 8.91 |
| Operating Income | -118 | -289 | -166 | -129 |
| Net Income | -9.02 | -295 | -170 | -91.70 |
| Shares Outstanding | 372 | 334 | 306 | 272 |
| Earnings Per Share | - | -0.11 | -0.07 | -0.04 |
| Operating Cash Flow | -123 | -232 | -149 | -120 |
| Capital Expenditures | 61.63 | -32.89 | -20.10 | -12.91 |
| Free Cash Flow | -61.84 | -265 | -169 | -133 |
| Cash & Equivalents | 537 | 355 | 322 | 0.00 |
| Total Debt | 27.22 | 5.91 | 6.35 | - |
| Net Cash / Debt | 510 | 349 | 316 | 0.00 |
| Assets | 882 | 491 | 443 | - |
| Liabilities | 156 | 75.38 | 62.10 | - |
| Book Value | 726 | 415 | 381 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
GW Pharmaceuticals PLC |
| Country |
United Kingdom |
| Employees |
901 |
| CEO |
Justin D. Gover |
Stock Information
| Ticker Symbol |
GWPH |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Drug Manufacturers—General |
| Unique Identifier |
NASDAQ: GWPH |
| IPO Date |
May 1, 2013 |
Description
GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.